Linked In Blog - Sedgwick
Skip to content
Latest Coronavirus updates from Sedgwick Back to business solutions

Posts related to ‘CBD’

Search
Filter
View
Blog
July 19, 2021
Chris Harvey
VP, crisis solution
CBD and cannabis: With opportunity comes risk

An exclusive life sciences webinar hosted recently by Sedgwick’s brand protection experts offered insight into the latest product safety challenges facing medical device, pharmaceutical and life sciences companies, including an insightful discussion …

July 19, 2021 by Chris Harvey, VP, crisis solution
Blog
October 22, 2019
Chris Harvey
VP, crisis solution
Cannabis recalled without federal regulation

The product recall by Denver-based marijuana cultivator Bonsai Cultivation reminds us of the unique regulatory dynamic facing the cannabis industry. In this case, the cultivator – working with state officials – pulled marijuana products off the marke…

October 22, 2019 by Chris Harvey, VP, crisis solution
Blog
July 10, 2019
Chris Harvey
VP, crisis solution
When recalls are about more than consumers: Managing up and down the supply chain

When there’s a recall, consumers think of the name on the package. Often that brand is the single company believed to be responsible, and that company is the one whose reputation is diminished. Perhaps nowhere is this more apparent than the food indu…

July 10, 2019 by Chris Harvey, VP, crisis solution
Blog
June 25, 2019
Chris Harvey
VP, crisis solution
Closer FDA CBD product regulation – and recalls – appear inevitable

We’ve seen sweeping regulatory changes before, but the FDA’s anticipated regulation of cannabis and CBD-infused products – a market expected to reach more than $20B globally by 2024 – promises to pose significant and unprecedented challenges to food …

June 25, 2019 by Chris Harvey, VP, crisis solution
Blog
October 05, 2018
Dr. Reema Hammoud
AVP, clinical pharmacy
DEA and FDA clear Epidiolex: Where do we go from here?

On September 27, 2018, the Drug Enforcement Agency (DEA) made a remarkable move. The agency placed a cannabidiol (CBD) containing product, Epidiolex, into Schedule V (classified as having low potential for abuse) so that it could be manufactured in t…

October 05, 2018 by Dr. Reema Hammoud, AVP, clinical pharmacy
End of results.
Loading...